Advances in mitotic inhibitors for cancer treatment.

摘要: Based on their mechanism of action, anti-tumor drugs that target the cell cycle can be generally divided into three categories, namely, blocking DNA synthesis, causing damage, and disrupting mitotic processes. In terms inhibitors, most compounds used in clinic impair normal function spindles by targeting tubulins, basic building blocks microtubules. vivo, these often exhibit significant side effects, thus limiting efficacy. Mitotic processes are under tight control through surveillance mechanisms commonly termed checkpoints. Defects regulation checkpoints result genomic instability, which predisposes to malignant transformation. As cancer is consequence uncontrolled division, great efforts have been devoted discover mitosis, thereby halting division inducing catastrophe with minimal cytotoxicity nondividing or normally dividing cells. This review primarily focuses proteins explored as new targets for anti-cancer drug development during past decade.